These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30875237)

  • 1. Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, promotes angiogenesis in vitro.
    Safaeian L; Vaseghi G; Jabari H; Dana N
    Can J Physiol Pharmacol; 2019 May; 97(5):352-358. PubMed ID: 30875237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Pien Tze Huang on angiogenesis in vivo and in vitro.
    Shen AL; Hong F; Liu LY; Lin JM; Zhuang QC; Hong ZF; Peng J
    Chin J Integr Med; 2012 Jun; 18(6):431-6. PubMed ID: 22821655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethyl Acetate Fraction of Teucrium Polium Extract Abolishes Human Umbilical Vein Endothelial Cells (HUVEC) Tubulogenesis in Collagen Bed through Suppression of Cell Proliferation/VEGF Secretion.
    Askari V; Shamlou S; Mostafaie A; Khaleqi S
    Iran J Allergy Asthma Immunol; 2019 Jun; 18(3):281-288. PubMed ID: 31522435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-angiogenic activity of notoginsenoside R1 in human umbilical vein endothelial cells in vitro and in a chemical-induced blood vessel loss model of zebrafish in vivo.
    Yang BR; Hong SJ; Lee SM; Cong WH; Wan JB; Zhang ZR; Zhang QW; Zhang Y; Wang YT; Lin ZX
    Chin J Integr Med; 2016 Jun; 22(6):420-9. PubMed ID: 25533511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xiongshao capsule promotes angiogenesis of HUVEC via enhancing cell proliferation and up-regulating the expression of bFGF and VEGF.
    Lin JM; Zhao JY; Zhuang QC; Hong ZF; Peng J
    Chin J Integr Med; 2011 Nov; 17(11):840-6. PubMed ID: 22057413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
    Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
    Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docosahexaenoic acid reverses the promoting effects of breast tumor cell-derived exosomes on endothelial cell migration and angiogenesis.
    Ghaffari-Makhmalbaf P; Sayyad M; Pakravan K; Razmara E; Bitaraf A; Bakhshinejad B; Goudarzi P; Yousefi H; Pournaghshband M; Nemati F; Fahimi H; Rohollah F; Hasanzad M; Hashemi M; Mousavi SH; Babashah S
    Life Sci; 2021 Jan; 264():118719. PubMed ID: 33159957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
    Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
    Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
    Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
    J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of calcitonin gene-related peptide on proliferation and migration of human umbilical vein endothelial cells].
    Tuo Y; Guo X; Zhang X; Wang Z; Zhou J; Zhang Y; Xia L; Wen J; Jin D
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2012 Apr; 26(4):495-500. PubMed ID: 22568336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulphonated Formononetin Induces Angiogenesis through Vascular Endothelial Growth Factor/cAMP Response Element-Binding Protein/Early Growth Response 3/Vascular Cell Adhesion Molecule 1 and Wnt/β-Catenin Signaling Pathway.
    Dong Z; Shi Y; Zhao H; Li N; Ye L; Zhang S; Zhu H
    Pharmacology; 2018; 101(1-2):76-85. PubMed ID: 29131133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oleanolic acid inhibits proliferation of HUVECs, and inhibits migration and tube formation via VEGF pathway].
    Wei JT; Liu M; Liu HZ; Zhao J; Xiao L; Han LJ; Lin XK
    Yao Xue Xue Bao; 2012 Nov; 47(11):1457-62. PubMed ID: 23387077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
    Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
    J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC; Watts GF; Somaratne R; Wasserman SM; Scott R; Barrett PHR
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
    Sattar N; Toth PP; Blom DJ; Koren MJ; Soran H; Uhart M; Elliott M; Cyrille M; Somaratne R; Preiss D
    Am J Cardiol; 2017 Nov; 120(9):1521-1527. PubMed ID: 28844508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
    Schmitz J; Gouni-Berthold I
    Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of cryptotanshinone on angiogenesis and Wnt/β-catenin signaling pathway in human umbilical vein endothelial cells.
    Chen Q; Zhuang Q; Mao W; Xu XM; Wang LH; Wang HB
    Chin J Integr Med; 2014 Oct; 20(10):743-50. PubMed ID: 24740553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.